USA flag logo/image

An Official Website of the United States Government

First Generation of Controlled-Release Bacteriocins/Anti-Microbials

Award Information

Agency:
Department of Defense
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
A2-5182
Solicitation Year:
2011
Solicitation Topic Code:
A11-127
Solicitation Number:
2011.3
Small Business Information
Orbis Biosciences, Inc.
2002 West 39th Avenue Kansas City, KS -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2013
Title: First Generation of Controlled-Release Bacteriocins/Anti-Microbials
Agency: DOD
Contract: W911QY-13-C-0025
Award Amount: $491,330.00
 

Abstract:

Combat ration Intermediate Moisture (IM) products currently use low pH and water content (aw) to discourage bacterial growth. The long-term goal of this SBIR project is to maintain the microbial stability of IM ration components over a three-year shelf life while increasing the pH and aw values for an improved organoleptic profile by incorporation of First Generation Controlled Release Bacteriocin/Antimicrobial (FGCRB/A). The specific objective of this Phase II application is to develop microspheres for continuous, controlled-release of antimicrobials capable of maintaining the microbial stability of IM rations with improved organoleptic characteristics after exposure to all of the relevant food manufacturing processes. This approach will provide for a safe, high-quality IM ration platform that satisfies the Warfighterfs demand for variety and palatability while reducing the amount of chemical preservatives. Orbis is uniquely qualified to achieve this objective because of our microparticle fabrication expertise, patented particle fabrication technology, and partnership with shelf-stable food experts at RDI Foods. We will also develop a cost-effective, scalable manufacturing process for bisin, the first bacteriocin effective against both gram-positive and gram-negative pathogens and incorporate this ingredient into our Phase II FGCRB/A prototype.

Principal Investigator:

David Dumbauld
Business Development Mana
(913) 945-7796
david@orbisbio.com

Business Contact:

Maria Flynn
President and CEO
(913) 945-6754
maria@orbisbio.com
Small Business Information at Submission:

Orbis Biosciences
2002 West 39th Avenue Kansas City, KS -

EIN/Tax ID: 262360301
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No